InnoCare Pharma announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in China.
InnoCare Pharma announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in China.